MXCT

Business Context and Reporting Period

Company: MaxCyte, Inc. (MXCT)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: MaxCyte is a commercial cell engineering company providing Flow Electroporation technology (ExPERT platform) for the discovery, development, and commercialization of cell and gene therapies. The company generates revenue through instrument sales/licenses, single-use processing assemblies (PAs), consumables, and Strategic Platform License (SPL) agreements that include milestone and sales-based payments.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 15% to $33.0 million. This was driven by a 44% drop in SPL program-related revenue ($3.4 million vs. $6.1 million) due to fewer clinical milestones achieved, and a 9% decline in core revenue ($29.6 million vs. $32.5 million) due to lower sales of PAs and licenses.
• Restructuring: The company implemented a workforce reduction plan in September 2025, reducing the global workforce by approximately 34%. This resulted in $3.1 million in restructuring expenses, compared to none in 2024.
• Goodwill Impairment: A non-cash goodwill impairment charge of $3.6 million was recorded in Q4 2025 following the acquisition of SeQure Dx. No such charge existed in 2024.
• Acquisition: In January 2025, MaxCyte acquired SeQure Dx for approximately $2.3 million to expand its gene-editing assessment services. SeQure contributed $1.1 million in revenue and $5.3 million in net loss for the partial year.
• Operating Expenses: Sales and marketing expenses decreased 29% to $18.9 million, and R&D expenses decreased 6% to $20.8 million, largely due to headcount reductions and lower stock-based compensation.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management expects existing cash, cash equivalents, and short-term investments ($103.0 million as of year-end) to fund operations for at least the next 12 months. The company projects ending 2026 with at least $136 million in total cash and investments.
• Stock Listing Risk: On March 16, 2026, MaxCyte received notice from Nasdaq that its common stock failed to meet the minimum bid price requirement ($1.00 per share) for 30 consecutive trading days. The company has an initial 180-day compliance period (until September 14, 2026) to regain compliance or risk delisting.
• Revenue Volatility: Future revenue remains highly dependent on the clinical progress of customers under SPL agreements. Milestone payments are unpredictable and subject to regulatory approvals and customer program continuance.
• Customer Concentration: One customer accounted for 26% of total revenue in 2025, and the five largest customers accounted for approximately 42% of total revenue.
• Profitability: The company expects to continue incurring net losses for the foreseeable future as it invests in R&D, commercial expansion, and new product development.

Key Facts for Investor Verification

• Nasdaq Compliance: Verify the company's progress in regaining compliance with the $1.00 minimum bid price requirement by September 14, 2026, to avoid delisting.
• SPL Milestone Realization: Monitor the clinical progress of the 13 active clinical programs under SPL agreements, as future revenue is heavily tied to these milestones (potential upside >$130 million).
• SeQure Integration: Assess the financial performance and integration of the SeQure Dx acquisition, which contributed to the goodwill impairment and increased operating complexity.
• Cash Burn Rate: Track the net cash used in operating activities ($34.4 million in 2025) against the $103 million liquidity position to ensure the 12-month runway remains valid.
• Customer Concentration: Evaluate the risk associated with the top customer representing 26% of revenue and the potential impact of any program discontinuation by major partners.